Biotechnology Bulletin ›› 2023, Vol. 39 ›› Issue (7): 316-324.doi: 10.13560/j.cnki.biotech.bull.1985.2022-1418
Previous Articles Next Articles
ZHOU Wen-han(), ZHENG Kang-ning, LI Yong-min()
Received:
2022-11-16
Online:
2023-07-26
Published:
2023-08-17
Contact:
LI Yong-min
E-mail:617982358@qq.com;liyongmin2001@sina.com
ZHOU Wen-han, ZHENG Kang-ning, LI Yong-min. Stellera chamaejasme L. Inhibiting Cell Proliferation by Reducing YAP1 Expression in Hepatocellular Carcinoma[J]. Biotechnology Bulletin, 2023, 39(7): 316-324.
Fig. 1 Effects of low concentration of SCL serum on the proliferation of normal liver cells L02 A: The effect of SCL decoction on the morphological appearance of liver.B: Proliferative effect of low concentration of SCL containing serum on L02 cells(*P<0.05). NS serum: Normal saline serum group; SCL serum : Stellera chamaejasme L. serum group
Fig. 2 Proliferation of HepG2215 cells inhibited by different concentrations of SCL serum A: The effects of different concentrations of SCL serum on the morphologyies of HepG2215 cells. Bar = 50 μm. B: The effects of different concentrations of SCL serum on the survival rates of HepG2215 cells. C: The IC50 values of HepG2215 cells treated with SCL serum for 24 h. *P<0.05, NS serum: Normal saline serum group. SCL serum: Stellera chamaejasme L. serum group
Fig. 3 Expression of YAP1 decreased by SCL serum in HepG2215 cells Expression of YAP1 in HepG2215 cells(*P<0.05). NS serum: Normal saline serum group. SCL serum: Stellera chamaejasme L. serum group
Fig. 4 SCL inhibiting tumor growth in the mice with hepatic carcinoma in situ A: Morphological appearance of the liver and the volume of liver tumors(*P<0.05). B: H&E staining of liver tumors. Bar = 100 μm. NS: Normal saline group, SCL: Stellera chamaejasme L. decoction group
Fig. 5 Expression of YAP1 decreased by SCL in the mice with tumors in liver Expression of YAP1 in the mice with tumors in liver(*P<0.05). NS: normal saline group. SCL: Stellera chamaejasme L. decoction group
Fig. 6 Venn diagram of the number of compounds of different groups detected by LC-MS A: Number of compounds detected by LC-MS negative electrode in different groups. B: Number of compounds detected by LC-MS positive electrode in different groups. NS serum: Normal saline serum group. SCL serum: Stellera chamaejasme L. serum group. SCL decoction: Stellera chamaejasme L. decoction group
化合物 Compound | 峰ID ID | 代谢物Metabolite | 离子模式 Mode | 加合离子模式 Adducts | 分子式 Formula | Metlin数据库得分 Fragmentation score | HMDB 数据库得分 Theoretical fragmentation score | 生理盐水组M_4 | 瑞香狼毒组 M_5 | 瑞香狼毒水煎液组W_6 |
---|---|---|---|---|---|---|---|---|---|---|
2.89_240.9800m/z | neg_1438 | 3-硫酸咖啡酸Caffeic acid 3-sulfate | neg | M-H2O-H | C9H8O7S | - | 87.8 | 0 | 42 837.95 | 4 520 349 |
6.01_213.0311m/z | neg_2060 | 5-苄恶唑-2-酮5-Benzyloxolan-2-one | neg | M+K-2H | C11H12O2 | - | 73.3 | 0 | 7 321.147 | 7 124.684 |
2.33_337.0552m/z | neg_5643 | 3,4,5-三羟基-6-[(2-氧代-2H-铬-5-基)氧]氧烷-2-羧酸 3,4,5-Trihydroxy-6-[(2-oxo-2H-chromen-5-yl)oxy]oxane-2-carboxylic acid | neg | M-H | C15H14O9 | - | 54.7 | 0 | 56 091.29 | 34 451.94 |
2.51_193.0492m/z | pos_1816 | 异东莨菪内酯Isoscopoletin | pos | M+H | C10H8O4 | 89.9 | - | 0 | 227.2022 | 5 515 259 |
Table 1 Active ingredients of SCL
化合物 Compound | 峰ID ID | 代谢物Metabolite | 离子模式 Mode | 加合离子模式 Adducts | 分子式 Formula | Metlin数据库得分 Fragmentation score | HMDB 数据库得分 Theoretical fragmentation score | 生理盐水组M_4 | 瑞香狼毒组 M_5 | 瑞香狼毒水煎液组W_6 |
---|---|---|---|---|---|---|---|---|---|---|
2.89_240.9800m/z | neg_1438 | 3-硫酸咖啡酸Caffeic acid 3-sulfate | neg | M-H2O-H | C9H8O7S | - | 87.8 | 0 | 42 837.95 | 4 520 349 |
6.01_213.0311m/z | neg_2060 | 5-苄恶唑-2-酮5-Benzyloxolan-2-one | neg | M+K-2H | C11H12O2 | - | 73.3 | 0 | 7 321.147 | 7 124.684 |
2.33_337.0552m/z | neg_5643 | 3,4,5-三羟基-6-[(2-氧代-2H-铬-5-基)氧]氧烷-2-羧酸 3,4,5-Trihydroxy-6-[(2-oxo-2H-chromen-5-yl)oxy]oxane-2-carboxylic acid | neg | M-H | C15H14O9 | - | 54.7 | 0 | 56 091.29 | 34 451.94 |
2.51_193.0492m/z | pos_1816 | 异东莨菪内酯Isoscopoletin | pos | M+H | C10H8O4 | 89.9 | - | 0 | 227.2022 | 5 515 259 |
Fig. 7 Schematic diagram of molecular docking between the active ingredients of Stellera chamaejasme L. and YAP1 A: Caffeic acid 3-sulfate and YAP1. B: 3,4,5-trihydroxy-6-[(2-oxo-2H-chromen-5-yl)oxy]oxane-2-carboxylic acid and YAP1. C: Isoscopoletin and YAP1.D:Verteporfin and YAP1
[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2018, 68(6): 394-424.
doi: 10.3322/caac.v68.6 URL |
[2] | Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta BBA Rev Cancer, 2020, 1873(1): 188314. |
[3] |
Imajo M, Ebisuya M, Nishida E. Dual role of YAP and TAZ in renewal of the intestinal epithelium[J]. Nat Cell Biol, 2015, 17(1): 7-19.
doi: 10.1038/ncb3084 |
[4] | Thompson BJ. YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy[J]. Bioessays, 2020, 42(5): e1900162. |
[5] | 王琪, 邓志华. 短发夹RNA沉默YAP表达对肝癌细胞SMMC-7721增殖和凋亡的影响[J]. 中国药物与临床, 2013, 13(9): 1117-1120, 1245. |
Wang Q, Deng ZH. Effects of shRNA on human hepatocellular carcinoma cell line SMMC-7721 apoptosis and proliferation via Yes-associated protein expression silencing[J]. Chin Remedies & Clin, 2013, 13(9): 1117-1120, 1245. | |
[6] |
Yang ZY, Kan JT, Cheng ZY, et al. Daphnoretin-induced apoptosis in HeLa cells: a possible mitochondria-dependent pathway[J]. Cytotechnology, 2014, 66(1): 51-61.
doi: 10.1007/s10616-013-9536-8 URL |
[7] | 刘阳, 卢年华, 冯亭亭, 等. HPLC结合响应面分析法优化提取瑞香狼毒中西瑞香素的含量研究[J]. 河北中医药学报, 2019, 34(5): 48-52. |
Liu Y, Lu NH, Feng TT, et al. Optimization of Daphne content extraction in Stellera chamaejasme by HPLC combined with response surface methodology[J]. J Hebei Tradit Chin Med Pharmacol, 2019, 34(5): 48-52. | |
[8] | Guo YL, Peng Q, Hao LY, et al. Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma[J]. FASEB J, 2022, 36(6): e22361. |
[9] |
Li SH, Ji JM, Zhang ZQ, et al. Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1[J]. Mol Cell Biochem, 2020, 475(1): 79-91.
doi: 10.1007/s11010-020-03861-0 |
[10] | 潘国凤, 杨庆, 翁小刚, 等. 瑞香狼毒抗肿瘤作用机制研究进展[J]. 中华中医药杂志, 2007, 22(12): 873-875. |
Pan GF, Yang Q, Weng XG, et al. Research progress on anti-tumor mechanism of stellera chamaejasme[J]. China J Tradit Chin Med Pharm, 2007, 22(12): 873-875. | |
[11] | 周芳月, 李佳, 潘泽政, 等. Hippo-YAP通路在多种干细胞尤其是卵巢生殖干细胞自我更新中作用的研究[J]. 中国细胞生物学学报, 2015, 37(7): 1053-1058. |
Zhou FY, Li J, Pan ZZ, et al. Research progress on the role of hippo-YAP pathway in regulating various stem cells especially ovarian germ stem cell self-renewal[J]. Chin J Cell Biol, 2015, 37(7): 1053-1058. | |
[12] |
Zhang X, Qiao YX, Wu Q, et al. The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis[J]. Nat Commun, 2017, 8: 15280.
doi: 10.1038/ncomms15280 pmid: 28474680 |
[13] |
Hao LY, Guo YL, Peng Q, et al. Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma[J]. Phytomedicine, 2022, 96: 153913.
doi: 10.1016/j.phymed.2021.153913 URL |
[14] | Xu ZH, Qin GW, Li XY, et al. New biflavanones and bioactive compounds from Stellera chamaejasme L[J]. Yao Xue Xue Bao, 2001, 36(9): 669-671. |
[15] |
Liu XN, Wang S, Yang Q, et al. ESC reverses epithelial mesenchymal transition induced by transforming growth factor-β via inhibition of Smad signal pathway in HepG2 liver cancer cells[J]. Cancer Cell Int, 2015, 15: 114.
doi: 10.1186/s12935-015-0265-2 URL |
[16] |
Kan XX, Li Q, Chen X, et al. A novel cell cycle blocker extracted from Stellera chamaejasme L. inhibits the proliferation of hepatocarcinoma cells[J]. Oncol Rep, 2016, 35(6): 3480-3488.
doi: 10.3892/or.2016.4742 URL |
[17] |
Zhao DD, Zhao QS, Liu L, et al. Compounds from Dryopteris fragrans(L.) schott with cytotoxic activity[J]. Molecules, 2014, 19(3): 3345-3355.
doi: 10.3390/molecules19033345 URL |
[18] |
McGovern PE, Christofidou-Solomidou M, Wang W, et al. Anticancer activity of botanical compounds in ancient fermented beverages(review)[J]. Int J Oncol, 2010, 37(1): 5-14.
pmid: 20514391 |
[19] | 杨喜花, 王俊田, 陈丽霞, 等. 瑞香狼毒提取物对肝癌原位移植瘤小鼠的生命延长作用[J]. 中国药物与临床, 2017, 17(4): 501-503. |
Yang XH, Wang JT, Chen LX, et al. Effect of stellera chamaejasme extract on prolonging life of mice with orthotopic liver cancer transplantation[J]. Chin Remedies & Clin, 2017, 17(4): 501-503. |
[1] | ZHANG Zu-lin, LIU Fang-fang, ZHOU Qing-niao, ZHAO Rui-qiang, HE Shu-jia, LIN Wen-zhen. Construction and Identification of Huh7 Hepatoma Cell Line with ACE2 Gene Knockout Based on CRISPR/Cas9 Technology [J]. Biotechnology Bulletin, 2023, 39(6): 181-188. |
[2] | WEI Zhi-han, FA Bo-tao, YU Zhang-sheng. Application of Multigene Model in Prognosis Prediction of Hepatocellular Carcinoma [J]. Biotechnology Bulletin, 2020, 36(5): 183-192. |
[3] | LIU Wen-rong ,DING Ruo-fan, ZHANG Yi-ming ,LI Yu-peng, LI Ling ,GUO Zhi-yun. Transcriptome Sequencing Analysis of Hepatocellular Carcinoma HepG2 Cells Induced by Antitumor Peptide 9R-P201 [J]. Biotechnology Bulletin, 2017, 33(7): 210-215. |
[4] | LI Yu-peng ,ZHANG Yi-ming,HU Hai-bi ,KANG Cheng-yu, LI Mu-zhou ,GUO Zhi-yun. Bioinformatics Analysis and Functional Verification of p53 Regulating miRNA-3661 in Hepatoma Cell HepG2 [J]. Biotechnology Bulletin, 2017, 33(7): 216-223. |
[5] | YANG Ya-lan, GUO Zhi-yun, DING Ruo-fan, MAO Can-quan, GUO Jian-xiu, XIONG Li-li. Differential Expression Profile Analysis of MicroRNAs in Doxorubicin-induced Hepatoma Cell Line HepG2 [J]. Biotechnology Bulletin, 2016, 32(6): 244-249. |
[6] | YAO Yang, SU Jie, LIU Kai-ge, Xu Rui. Function Analysis of Up-regulated Gene(URG11)Based on Its Bioinformatics [J]. Biotechnology Bulletin, 2016, 32(3): 203-208. |
[7] | ZHANG Wen-mei, DING Yan, GUO Xing-rong, LI Dong-sheng, ZHAO Wan-hong, WANG Xiao-li. The Establishment of HepG2 Cell Line with TALEN-mediated Knockout of CXCR4 [J]. Biotechnology Bulletin, 2016, 32(2): 225-228. |
[8] | Zhao Yinghua, Sun Wei. Research Advances on the Applications of Hepatocellular Carcinoma Transgenic Mouse Models [J]. Biotechnology Bulletin, 2015, 31(12): 56-62. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||